Interview with: Eric H. Bjerkholt, CFO - featuring: their small molecule therapeutics for oncology, including clinical trials for acute leukemia, ovarian cancer and other serious diseases.

Sunesis Pharmaceuticals Inc. (SNSS-NASDAQ)

CURRENT ISSUE |  COVER ARCHIVES  |  INDEX  |  CONTACT  |  FINANCIALS |  MARKETING SERVICES | HOME PAGE

CEOCFO-Members Login
Become A Member!

This is a printer friendly page!

Sunesis Pharmaceuticals has developed a portfolio of cancer drug candidates that target the cell cycle, which gives preferentially target cancer cells that are rapidly dividing



Healthcare
Biotechnology
(SNSS-NASDAQ)

Sunesis Pharmaceuticals Inc.




Eric H. Bjerkholt
Chief Financial Officer

Interview conducted by:
Lynn Fosse, Senior Editor
CEOCFOinterviews.com
April 20, 2006

disclaimers

Any reproduction or further distribution of this article without the express written consent of CEOCFOinterviews.com is prohibited.

“Our most advanced product candidate is called SNS-595; it is a novel cell cycle inhibitor and it is currently in two Phase II trials for non-small cell lung cancer and small cell cancer. We also have it in Phase I study for acute leukemia and later this year we plan to start a Phase II trial in ovarian cancer. Our second product candidate is called a SNS-032; it is a novel CDK inhibitor; it is an inhibitor of CDK 2, 7 & 9. Currently we have one trial that is ongoing, it is Phase I/II dose escalation safety study in advanced solid tumors. In the second half of this year, we will start a second trial, which will be a Phase I trial in B-cell malignancies. Our third product candidate is called SNS-314; it is an Aurora kinase inhibitor that is currently undergoing preclinical toxicology studies and the goal there is to file an IND (Investigational New Drug application) before the end of this year and commence Phase I clinical studies in early 2007.” - Eric H. Bjerkholt